Survodutide

Observations from clinical literature.

• Dose‑dependent weight loss of 12.5–14.9% (vs placebo) over 46 weeks in phase 2 obesity trials.
• Improvements in liver‑related biomarkers in NAFLD/NASH populations.
• Meta‑analysis confirms consistent weight‑loss efficacy across multiple randomized controlled trials.
• Adverse effects are primarily gastrointestinal: nausea, vomiting, diarrhea, and constipation (most common during dose escalation).
• Gradual titration helps mitigate GI tolerability issues.

Intended Use: MOTS-c is designed for Research Purposes only.

Storage: Store the vial in a cool, dry place away from direct sunlight. Once reconstituted, keep refrigerated at 2-8°C.

Solubility: Reconstitute with bacteriostatic water for best results.

Shelf Life: The lyophilized form has a shelf life of 24 months when properly stored. Once reconstituted, refrigerate and use within 4-6 weeks.

Handling: Ensure sterile techniques are used to maintain the product’s integrity during research.